ICAM-2, CAS No.rp174245

CAS: rp174245 Cat. No.: rp174245

GRADE & PURITY Moligand™

Specifications

Product Name

ICAM-2, CAS No.rp174245

Grade

Moligand™

Specifications & Purity

Moligand™

CAS

rp174245

Molecule Type

Peptide

Storage and Shipping

Storage

Room temperature

Genetic information

• Reference:
  • 1. Kinetics and inhibition of recombinant human cystathionine gamma-lyase. Toward the rational control of transsulfuration., The Journal of biological chemistry, Steegborn, C C and 7 more authors.
  • 2. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences., Proceedings of the National Academy of Sciences of the United States of America, Strausberg, Robert L RL and 83 more authors.
  • 3. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH)., Human genetics, Wang, Jian J and Hegele, Robert A RA.
  • 4. Cloning and nucleotide sequence of human liver cDNA encoding for cystathionine gamma-lyase., Biochemical and biophysical research communications, Lu, Y Y, O'Dowd, B F BF, Orrego, H H and Israel, Y Y.
  • 5. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration., Clinical genetics, Wang, J J, Huff, A M AM, Spence, J D JD and Hegele, R A RA.
  • 6. Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1., The Journal of biological chemistry, Yang, Guangdong G, Cao, Kun K, Wu, Lingyun L and Wang, Rui R.
  • 7. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)., Genome research, Gerhard, Daniela S DS and 115 more authors.
  • 8. Towards a proteome-scale map of the human protein-protein interaction network., Nature, Rual, Jean-François JF and 37 more authors.
  • 9. The DNA sequence and biological annotation of human chromosome 1., Nature, Gregory, S G SG and 178 more authors.
  • 10. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer., International journal of cancer, Moore, Lee E LE and 14 more authors. more
  • 11. Toward a confocal subcellular atlas of the human proteome., Molecular & cellular proteomics : MCP, Barbe, Laurent L and 10 more authors.
  • 12. Kinetic properties of polymorphic variants and pathogenic mutants in human cystathionine gamma-lyase., Biochemistry, Zhu, Weidong W, Lin, Alexander A and Banerjee, Ruma R.
  • 13. Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway., Carcinogenesis, Hosgood, H Dean HD and 12 more authors.
  • 14. Relationship between cystathionine gamma-lyase gene polymorphism and essential hypertension in Northern Chinese Han population., Chinese medical journal, Li, Yun Y and 8 more authors.
  • 15. Active cystathionine beta-synthase can be expressed in heme-free systems in the presence of metal-substituted porphyrins or a chemical chaperone., The Journal of biological chemistry, Majtan, Tomas T, Singh, Laishram R LR, Wang, Liqun L, Kruger, Warren D WD and Kraus, Jan P JP.
  • 16. MALDI-TOF MS genotyping of polymorphisms related to 1-carbon metabolism using common and mass-modified terminators., Clinical chemistry, Meyer, Klaus K, Fredriksen, Ase A and Ueland, Per Magne PM.
  • 17. Structural basis for the inhibition mechanism of human cystathionine gamma-lyase, an enzyme responsible for the production of H(2)S., The Journal of biological chemistry, Sun, Qingxiang Q and 10 more authors.
  • 18. Oral facial clefts and gene polymorphisms in metabolism of folate/one-carbon and vitamin A: a pathway-wide association study., Genetic epidemiology, Boyles, Abee L AL and 16 more authors.
  • 19. Large-scale proteomics and phosphoproteomics of urinary exosomes., Journal of the American Society of Nephrology : JASN, Gonzales, Patricia A PA and 7 more authors.
  • 20. An association study of 45 folate-related genes in spina bifida: Involvement of cubilin (CUBN) and tRNA aspartic acid methyltransferase 1 (TRDMT1)., Birth defects research. Part A, Clinical and molecular teratology, Franke, Barbara B and 7 more authors.
  • 21. Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China., Environmental and molecular mutagenesis, Shen, Min M and 12 more authors.
  • 22. H2S biogenesis by human cystathionine gamma-lyase leads to the novel sulfur metabolites lanthionine and homolanthionine and is responsive to the grade of hyperhomocysteinemia., The Journal of biological chemistry, Chiku, Taurai T and 5 more authors.
  • 23. Variations in folate pathway genes are associated with unexplained female infertility., Fertility and sterility, Altmäe, Signe S and 7 more authors.
  • 24. Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation., World journal of gastroenterology, Renga, Barbara B, Mencarelli, Andrea A, Migliorati, Marco M, Distrutti, Eleonora E and Fiorucci, Stefano S.
  • 25. Cystathionine gamma-lyase: Clinical, metabolic, genetic, and structural studies., Molecular genetics and metabolism, Kraus, Jan P JP and 14 more authors.
  • 26. Relative contributions of cystathionine beta-synthase and gamma-cystathionase to H2S biogenesis via alternative trans-sulfuration reactions., The Journal of biological chemistry, Singh, Sangita S, Padovani, Dominique D, Leslie, Rachel A RA, Chiku, Taurai T and Banerjee, Ruma R.
  • 27. PTEN identified as important risk factor of chronic obstructive pulmonary disease., Respiratory medicine, Hosgood, H Dean HD, Menashe, Idan I, He, Xingzhou X, Chanock, Stephen S and Lan, Qing Q.
  • 28. Genetic susceptibility to distinct bladder cancer subphenotypes., European urology, Guey, Lin T LT and 18 more authors.
  • 29. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip., American journal of human genetics, Talmud, Philippa J PJ and 38 more authors.
  • 30. Integrative predictive model of coronary artery calcification in atherosclerosis., Circulation, McGeachie, Michael M and 13 more authors.
  • 31. Cystathionine beta-synthase 844Ins68 polymorphism is not associated with the levels of homocysteine and cysteine in an Indian population., Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, Kumar, Jitender J, Garg, Gaurav G, Karthikeyan, Ganesan G and Sengupta, Shantanu S.
  • 32. The expression and activity of cystathionine-γ-lyase and 3-mercaptopyruvate sulfurtransferase in human neoplastic cell lines., Amino acids, Jurkowska, Halina H, Placha, Wojciech W, Nagahara, Noriuki N and Wróbel, Maria M.
  • 33. Ancient origin of the CTH alelle carrying the c.200C>T (p.T67I) variant in patients with cystathioninuria., Clinical genetics, Espinós, C C and 8 more authors.
  • 34. Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study., Diabetes care, Bailey, Swneke D SD and 11 more authors.
  • 35. Maternal genes and facial clefts in offspring: a comprehensive search for genetic associations in two population-based cleft studies from Scandinavia., PloS one, Jugessur, Astanand A and 12 more authors.
  • 36. [Expression of cystathionine-γ-lyase/hydrogen sulfide pathway in CVB3-induced myocarditis in mice]., Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, Hua, Wang W and 6 more authors.
  • 37. Folate-metabolizing gene variants and pregnancy outcome of IVF., Reproductive biomedicine online, Laanpere, M M and 5 more authors.
  • 38. Specificity protein-1 as a critical regulator of human cystathionine gamma-lyase in smooth muscle cells., The Journal of biological chemistry, Yang, Guangdong G, Pei, Yanxi Y, Teng, Huajian H, Cao, Qiuhui Q and Wang, Rui R.
  • 39. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium., Briefings in bioinformatics, Gaudet, Pascale P, Livstone, Michael S MS, Lewis, Suzanna E SE and Thomas, Paul D PD.
  • 40. Expression of cystathionine β-synthase and cystathionine γ-lyase in human pregnant myometrium and their roles in the control of uterine contractility., PloS one, You, Xing-Ji XJ and 8 more authors.
  • 41. MicroRNA-21 represses human cystathionine gamma-lyase expression by targeting at specificity protein-1 in smooth muscle cells., Journal of cellular physiology, Yang, Guangdong G, Pei, Yanxi Y, Cao, Qiuhui Q and Wang, Rui R.
  • 42. H2S-Induced sulfhydration of the phosphatase PTP1B and its role in the endoplasmic reticulum stress response., Science signaling, Krishnan, Navasona N, Fu, Cexiong C, Pappin, Darryl J DJ and Tonks, Nicholas K NK.
  • 43. Characterization of hydrogen sulfide and its synthases, cystathionine β-synthase and cystathionine γ-lyase, in human prostatic tissue and cells., Urology, Guo, Hui H and 5 more authors.
  • 44. Sp1 is involved in regulation of cystathionine γ-lyase gene expression and biological function by PI3K/Akt pathway in human hepatocellular carcinoma cell lines., Cellular signalling, Yin, Peng P and 12 more authors.
  • 45. H₂S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase., Circulation, Kondo, Kazuhisa K and 14 more authors.
  • 46. Reduced cystathionine γ-lyase and increased miR-21 expression are associated with increased vascular resistance in growth-restricted pregnancies: hydrogen sulfide as a placental vasodilator., The American journal of pathology, Cindrova-Davies, Tereza T and 5 more authors.
  • 47. Dysregulation of hydrogen sulfide producing enzyme cystathionine γ-lyase contributes to maternal hypertension and placental abnormalities in preeclampsia., Circulation, Wang, Keqing K and 14 more authors.
  • 48. Regulation of cystathionine γ-lyase in mammalian cells by hypoxia., Biochemical genetics, Wang, Maoxian M, Guo, Zhanyun Z and Wang, Shilong S.
  • 49. A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients., Breast cancer research : BCR, Chung, Suyoun S and 6 more authors.
  • 50. [Cystathionine γ-lyase]., Postepy higieny i medycyny doswiadczalnej (Online), Jurkowska, Halina H, Kaczor-Kamińska, Marta M, Bronowicka-Adamska, Patrycja P and Wróbel, Maria M.
  • 51. Decreased cystathionine-γ-lyase (CSE) activity in livers of type 1 diabetic rats and peripheral blood mononuclear cells (PBMC) of type 1 diabetic patients., The Journal of biological chemistry, Manna, Prasenjit P, Gungor, Neslihan N, McVie, Robert R and Jain, Sushil K SK.
  • 52. Hydrogen sulfide (H2S)/cystathionine γ-lyase (CSE) pathway contributes to the proliferation of hepatoma cells., Mutation research, Pan, Yan Y and 5 more authors.
  • 53. The cystathionine γ-lyase/hydrogen sulfide system maintains cellular glutathione status., The Biochemical journal, Lee, Zheng-Wei ZW, Low, Yi-Lian YL, Huang, Shufen S, Wang, Tianxiao T and Deng, Lih-Wen LW.
  • 54. The binding site for the transcription factor, NF-κB, on the cystathionine γ-lyase promoter is critical for LPS-induced cystathionine γ-lyase expression., International journal of molecular medicine, Wang, Maoxian M, Guo, Zhanyun Z and Wang, Shilong S.
  • 55. Regulation of cystathionine gamma-lyase/H₂S system and its pathological implication., Frontiers in bioscience (Landmark edition), Zhao, Kexin K, Li, Hongzhu H, Li, Shuangshuang S and Yang, Guangdong G.
  • 56. Dysregulation of hydrogen sulphide metabolism impairs oviductal transport of embryos., Nature communications, Ning, Nannan N and 5 more authors.
  • 57. Wnt/β-catenin signaling induces the transcription of cystathionine-γ-lyase, a stimulator of tumor in colon cancer., Cellular signalling, Fan, Kun K and 7 more authors.
  • 58. miRNA-30 family inhibition protects against cardiac ischemic injury by regulating cystathionine-γ-lyase expression., Antioxidants & redox signaling, Shen, Yaqi Y and 7 more authors.
  • 59. Role of the cystathionine γ lyase/hydrogen sulfide pathway in human melanoma progression., Pigment cell & melanoma research, Panza, Elisabetta E and 11 more authors.
  • 60. A proteome-scale map of the human interactome network., Cell, Rolland, Thomas T and 69 more authors.
  • 61. Neurodegeneration in Huntington's disease involves loss of cystathionine γ-lyase., Cell cycle (Georgetown, Tex.), Paul, Bindu D BD and Snyder, Solomon H SH.
  • 62. The importance of MTHFR, MTR, MTRR and CSE expression levels in Caucasian women with preeclampsia., European journal of obstetrics, gynecology, and reproductive biology, Seremak-Mrozikiewicz, Agnieszka A and 6 more authors.
  • 63. The importance of rs1021737 and rs482843 polymorphisms of cystathionine gamma-lyase in the etiology of preeclampsia in the Caucasian population., Ginekologia polska, Mrozikiewicz, Przemysław M PM and 8 more authors.
  • 64. Cystathionine γ-lyase, a H2S-generating enzyme, is a GPBAR1-regulated gene and contributes to vasodilation caused by secondary bile acids., American journal of physiology. Heart and circulatory physiology, Renga, Barbara B and 9 more authors.
  • 65. Correlation between the cystathionine-γ-lyase (CES) and the severity of peptic ulcer disease., African health sciences, Chen, Xiong X, Wan, Ying-Chun YC, Guo, Tao T, Xu, Can-Xia CX and Wang, Fen F.
  • 66. MPST but not CSE is the primary regulator of hydrogen sulfide production and function in the coronary artery., American journal of physiology. Heart and circulatory physiology, Kuo, Maggie M MM and 10 more authors.
  • 67. Transcriptional Regulation of Cystathionine-γ-Lyase in Endothelial Cells by NADPH Oxidase 4-Dependent Signaling., The Journal of biological chemistry, Mistry, Rajesh K RK and 8 more authors.
  • 68. LPS Up-Regulates Cystathionine γ -Lyase Gene Expression in Primary Human Macrophages via NF-κB/ERK Pathway., Inflammation & allergy drug targets, Badiei, Alireza A, Gieseg, Steven S, Davies, Sian S, Izani Othman, Mohd M and Bhatia, Madhav M.
  • 69. Radiation Exposure Promotes Hepatocarcinoma Cell Invasion through Epithelial Mesenchymal Transition Mediated by H2S/CSE Pathway., Radiation research, Pan, Yan Y, Zhou, Cuiping C, Yuan, Dexiao D, Zhang, Jianghong J and Shao, Chunlin C.
  • 70. Cystathionine γ-lyase(CSE)/hydrogen sulfide system is regulated by miR-216a and influences cholesterol efflux in macrophages via the PI3K/AKT/ABCA1 pathway., Biochemical and biophysical research communications, Gong, Duo D and 15 more authors.
  • 71. MicroRNA-186 promotes macrophage lipid accumulation and secretion of pro-inflammatory cytokines by targeting cystathionine γ-lyase in THP-1 macrophages., Atherosclerosis, Yao, Yan Y and 9 more authors.
  • 72. Cystathionine γ-lyase is expressed in human atherosclerotic plaque microvessels and is involved in micro-angiogenesis., Scientific reports, van den Born, J C JC and 5 more authors.
  • 73. Dichotomous effects of isomeric secondary amines containing an aromatic nitrile and nitro group on human aortic smooth muscle cells via inhibition of cystathionine-γ-lyase., Biochimie, Ji, Yajing Y and 6 more authors.
  • 74. Distinctive expression pattern of cystathionine-β-synthase and cystathionine-γ-lyase identifies mesenchymal stromal cells transition to mineralizing osteoblasts., Journal of cellular physiology, Gambari, Laura L and 6 more authors.
  • 75. Age-Dependent Allergic Asthma Development and Cystathionine Gamma-Lyase Deficiency., Antioxidants & redox signaling, Wang, Peipei P and 6 more authors.
  • 76. Augmented H2S production via cystathionine-beta-synthase upregulation plays a role in pregnancy-associated uterine vasodilation., Biology of reproduction, Sheibani, Lili L and 7 more authors.
  • 77. Total sulfane sulfur bioavailability reflects ethnic and gender disparities in cardiovascular disease., Redox biology, Rajpal, Saurabh S and 12 more authors.
  • 78. Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides., Gene, Maruyama, K K and Sugano, S S.

Application Protocols

Authoritative item-specific protocols and conditions:

• Not specified for this item; refer to CoA/Spec Sheet.

General experimental outlines (literature/general; adapt to your assay and confirm compound compatibility):

• Biochemical binding assay (e.g., SPR/BLI/MST): Prepare serial dilutions in running buffer with matched DMSO. Confirm absence of aggregation by including detergent where appropriate and running control injections.
• Cell-based assay: Titrate compound across 8–12 concentrations, maintaining constant vehicle. Include cytotoxicity counterscreens and orthogonal readouts of ICAM-2–related function (e.g., leukocyte adhesion on endothelial monolayers expressing ICAM-2).
• Thermal shift/CETSA: Mix compound with target protein/cells, apply temperature gradient, and quantify stabilization by DSF or immunoblot. Ensure compound solubility at all temperatures and verify DMSO controls.

Note:

• These are general templates; the exact procedures, concentrations, and readouts must be tailored to the verified structure, solubility, and stability of this specific item.

Biological Roles

Context (general/literature, not item-specific claims):

• ICAM-2 (Intercellular Adhesion Molecule 2; CD102) is a type I transmembrane glycoprotein of the immunoglobulin superfamily expressed notably on endothelial cells, some leukocyte subsets, and platelets. It participates in leukocyte adhesion and transmigration via interactions with integrins (e.g., LFA-1, Mac-1) and contributes to immune surveillance, vascular biology, and barrier function.
• In cell signaling terms, ICAM-2 engagement can modulate cytoskeletal dynamics and endothelial junctional organization, influencing diapedesis. Its expression is regulated by inflammatory cues, though typically less inducible than ICAM-1.

How this relates to a Moligand™ item named “ICAM-2” (general):

• A small-molecule tool compound labeled “ICAM-2” is commonly intended for studies probing pathways associated with ICAM-2 biology (e.g., adhesion, integrin interactions, endothelial function). The exact mechanism (agonist/antagonist/allosteric modulator) and biochemical potency/selectivity for this item are not provided here and must be verified from primary documentation.

Practical research notes:

• In designing assays, incorporate appropriate readouts (e.g., adhesion assays on ICAM-2–expressing cells, integrin binding assays, or endothelial barrier measurements) and include orthogonal controls. Confirm that the compound’s solubility and stability support the biological protocol.

Item-specific biological activity data:

• Not specified for this item; refer to CoA/Spec Sheet.

Buffer Applications

Applicability note:

• This product is a small-molecule/ligand entry with no disclosed acid/base functionality or buffering capacity. It is not intended as a buffer component.

General guidance (for handling only):

• If the compound is prepared as a stock in DMSO, dilute into the desired assay buffer (e.g., HEPES, PBS, Tris) ensuring the final organic solvent level is tolerated by the biological system. Optimize order of addition to prevent precipitation.

Item-specific buffer/formulation data:

• Not specified for this item; refer to CoA/Spec Sheet.

Green Alternatives

Applicability note:

• Without a disclosed structure or solvent requirement, recommending greener drop-in substitutes for this specific item is not applicable.

General considerations (literature/general):

• If the item requires organic dissolution, prefer greener solvents where assay-compatible, e.g., water/biobuffers > ethanol > 2-propanol > ethyl acetate > acetonitrile/MeOH > DMSO/DMF/NMP (rank depends on context and guidance from solvent selection guides). DMSO is widely used in screening but is not classified as particularly green; minimize volumes.
• Reduce environmental impact by:
  • Preparing the highest concentration stock feasible to minimize solvent waste.
  • Using miniaturized assay formats (384/1536-well) to cut solvent and plastic usage.
  • Implementing closed-well handling to reduce VOC emissions.
• For purification or analytics (if undertaken), select aqueous LC methods where possible and reuse mobile phases following lab safety and compliance procedures.

Pharmaceutical Uses

Applicability note:

• No pharmacopeial status, excipient role, or manufacturing use is provided for this item. It is supplied for research use only.

General context (literature/general):

• Small-molecule ligands associated with biological targets (like ICAM-2) are often employed in early discovery for target validation, assay development, or hit-to-lead exploration. They are not drug substances or drug products and are not intended for human or veterinary use.

Compliance reminder:

• For any work intersecting regulated environments, ensure segregation of research-use-only materials from GMP workflows. If scale-up or preclinical translation is contemplated, obtain comprehensive specifications, impurity profiles, and stability data under ICH conditions.

Item-specific pharmaceutical/formulation information:

• Not specified for this item; refer to CoA/Spec Sheet.

Physical Properties

Item-specific specifications:

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight (exact): Not specified for this item; refer to CoA/Spec Sheet.
• Melting point / Boiling point: Not specified for this item; refer to CoA/Spec Sheet.
• Density / Refractive index: Not specified for this item; refer to CoA/Spec Sheet.
• LogP / pKa / UV cutoff: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility: Not specified for this item; refer to CoA/Spec Sheet.

General guidance (literature/general, not item-specific):

• Small-molecule screening ligands are frequently supplied as dry powders or pre-dosed solids suitable for dissolution in polar aprotic solvents (e.g., DMSO) for biological assays; however, the appropriate solvent for this specific item must be verified from the CoA/Spec Sheet.
• If spectral purity data are provided by the supplier, typical confirmation includes LC–MS purity (>95% for screening quality in many libraries) and a single dominant peak in chromatographic traces; exact thresholds for this item are not provided here.

Quality & Grades

Item-specific fact:

• Grade/Purity: Moligand™ (as stated in Product Data).

Interpretation and guidance (general, not item-specific specifications):

• Moligand™ indicates placement within a small-molecule/ligand collection intended for discovery screening, target validation, or chemical biology applications. Such collections typically emphasize structural diversity, drug-like physicochemical space, and assay-ready handling. Exact purity thresholds, stabilizers, or salt forms for this item are not specified here—refer to the CoA/Spec Sheet for definitive values and QC metrics.
• Quality documentation to request/consult for this item:
  • LC–MS or HPLC purity trace (with method details and detection wavelength).
  • HRMS or exact-mass confirmation; optional 1H NMR/13C NMR if available.
  • Water content (Karl Fischer) and residual solvents, if relevant to your assay; Not specified for this item.
• Implications for use:
  • For biochemical screening, low background absorbance/fluorescence and minimal impurities are advantageous. Verify the supplier’s chromatographic purity and confirm identity prior to plate formatting.
  • If your assay is redox- or metal-sensitive, consider requesting information on residual metals/peroxides. Not specified for this item; refer to CoA/Spec Sheet.

Reaction & Applications

Item-specific manufacturer applications:

• None provided beyond the product title. No reaction-use claims are specified for this item.

Applicability note:

• A product named “ICAM-2” in a Moligand™ collection is typically a screening ligand or tool compound for biochemical/phenotypic assays rather than a synthetic reagent. As such, classical organic reaction applications (e.g., cross-coupling, reductions) are generally not the intended use case.

General research applications (literature/general):

• Use as a putative probe/ligand in target engagement assays (e.g., thermal shift, CETSA, DSF) or in binding studies (e.g., SPR, BLI, MST), provided structural and solubility details are confirmed for this specific item.
• Potential inclusion in cell-based phenotypic assays where ICAM-2–related pathways or adhesion phenotypes are monitored. Assay design must verify cell-permeability, stability, and non-specific toxicity for the compound on hand.
• For SAR or orthogonal validation, pair with reference standards (if available) and include negative controls and appropriate vehicle controls (DMSO).

Important:

• Because no structure or mechanistic annotations are supplied for this item, users should generate preliminary physchem and stability data (solubility, logD at assay pH, stability in buffer/media) before interpreting biological results.

Reaction Conditions

Applicability note:

• No synthetic or reaction-use information is provided for this item. It is not positioned as a reagent, catalyst, or building block.

General research handling (literature/general):

• For assay preparation, typical stock solutions of small-molecule ligands are made in DMSO at 10–50 mM and stored in sealed, inert containers with minimal freeze–thaw cycles. Exact concentrations and conditions for this item are not specified and should be determined experimentally based on solubility and assay needs.

Item-specific reaction/processing conditions:

• Not specified for this item; refer to CoA/Spec Sheet.

Safety & Handling

Item-specific hazard information from Product Data:

• Signal word (GHS): Not specified for this item; refer to SDS.
• H-statements / Pictograms / Classification: Not specified for this item; refer to SDS.

General safety guidance (always defer to the SDS as the authoritative source):

• Handle all research chemicals as potentially hazardous. Use appropriate PPE: lab coat, safety glasses, and chemical-resistant gloves. Work in a chemical fume hood to avoid inhalation of dusts/aerosols.
• Storage incompatibilities (general): Keep away from strong oxidizers and strong acids/bases unless compatibility is documented on the SDS/Spec Sheet. Avoid moisture if the compound is hygroscopic; store under desiccation if noted by the supplier.
• Spill/Exposure (overview): For small spills of solid compounds, avoid dust formation, collect with inert absorbent, and dispose of according to institutional protocols. In case of skin or eye contact, rinse with plenty of water for at least 15 minutes. Seek medical attention after any significant exposure.
• Waste disposal: Follow local regulations and institutional procedures for disposal of organic research chemicals.

Special notes:

• Because chemical structure and hazards for this specific item are not provided here, consult the SDS and CoA/Spec Sheet prior to first use for definitive precautions, incompatibilities, and first-aid measures.

Solvent Selection

Item-specific solubility and solvent guidance:

• Not specified for this item; refer to CoA/Spec Sheet.

General solvent selection strategy for small-molecule ligands (literature/general):

• Start with DMSO for stock solutions due to its broad solubilizing power and compatibility with many biochemical assays. If precipitation occurs upon dilution, co-solvent systems (e.g., DMSO:H2O with PEG-400 or ethanol as tertiary co-solvent) can help; confirm assay tolerance.
• Consider compound class–dependent alternatives:
  • Polar aprotic: DMF, NMP (use with care in biology due to cytotoxicity/leachables).
  • Protic: ethanol, isopropanol for rapid screening if compatible with the target assay.
  • Aqueous buffers: feasible only if the compound exhibits sufficient ionizable functionality.
• Practical tips:
  • Prepare concentrated DMSO stocks (e.g., 10–50 mM) and dilute into assay buffer keeping final DMSO ≤0.1–1% v/v as assay-appropriate (general guidance; verify against your protocol).
  • Filter sterilize only if the compound is filtration-stable and non-adsorptive to membranes; test recovery.
• For chromatography or purification (if applicable), choose eluents based on polarity and UV chromophore; in absence of structural data, scout broadly (MeCN/H2O or MeOH/H2O with formic acid or ammonium buffers for LC; hexanes/EtOAc gradients for normal-phase TLC scouting).

Storage & Reconstitution

Item-specific instructions from Product Data:

• Storage conditions: Room temperature.
• Shipped in: Not specified for this item; refer to CoA/Spec Sheet.

General handling and reconstitution guidance (literature/general; verify against this item’s Spec Sheet before use):

• Upon receipt, keep container tightly closed, protected from moisture and light. If the compound is hygroscopic or photosensitive (unknown here), consider desiccation and amber protection.
• For preparation of working stocks, dissolve in a suitable solvent (commonly DMSO for small-molecule ligands) to a convenient concentration (e.g., 10–50 mM), then aliquot to minimize freeze–thaw. Store aliquots according to demonstrated stability data; none are specified here.
• Before biological assays, equilibrate to room temperature and inspect for precipitation or discoloration. If precipitated upon dilution, adjust co-solvent ratio or warming gently; avoid prolonged heating.

Item-specific stability, re-test period, and reconstitution solvent:

• Not specified for this item; refer to CoA/Spec Sheet.

Research use note:

• For research use only.

Structure & Identity

Item-specific data from Product Data:

• Product Name: ICAM-2
• SKU: rp174245
• CAS (catalog placeholder): rp174245
• Grade/Purity: Moligand™
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.

Notes and context (general/literature):

• The name “ICAM-2” commonly refers to Intercellular Adhesion Molecule 2 (CD102), an endothelial/immune cell adhesion protein. In small-molecule collections, a product named “ICAM-2” typically denotes a ligand or tool compound intended for studies involving the ICAM-2 pathway or its interacting proteins. The exact chemical structure for this specific catalog item is not provided here.
• Without a disclosed structure, functional groups, rings, or stereochemistry cannot be detailed for this item. Consult the product’s CoA/Specification Sheet for definitive identity and structural descriptors.

Practical identification guidance (general):

• For compound library members, confirm identity by vendor-supplied characterization (e.g., LC–MS/HRMS, purity trace, and, if available, NMR). Match retention time and exact mass to the provided reference prior to screening or scale-up.

Synthetic Utility

Applicability note:

• Without structural information, this product cannot be positioned as a synthetic building block or reagent. It is primarily intended for screening and biological studies rather than for use in named organic transformations.

General guidance (if derivatization is considered; literature/general):

• If the structure becomes available and contains modifiable handles, analog generation (SAR) may be pursued to probe ICAM-2–related biology. Standard medicinal chemistry tactics (scaffold hopping, isosteres, polarity tuning) would then apply.

Item-specific reactivity/functional group notes:

• Not specified for this item; refer to CoA/Spec Sheet.

Target Specificity

Authoritative item-specific data:

• Not specified for this item; refer to CoA/Spec Sheet.

Context (general/literature):

• The name suggests relevance to the ICAM-2 (CD102) pathway. However, no binding constants, selectivity data, or on/off-target profiles are provided for this specific catalog entry. Users should generate or obtain direct evidence (e.g., KD, IC50/EC50, target engagement) before drawing conclusions about specificity.

Frequently Asked Questions

What are the CAS number, molecular formula and molecular weight?

The CAS Number is rp174245.